Embecta (NASDAQ:EMBC - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 2.700-2.900 for the period, compared to the consensus earnings per share estimate of 2.810. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Embecta Trading Down 1.7 %
Shares of NASDAQ EMBC traded down $0.31 during midday trading on Friday, reaching $17.42. 468,071 shares of the stock were exchanged, compared to its average volume of 324,383. The company has a market capitalization of $1.01 billion, a P/E ratio of 17.42, a P/E/G ratio of 0.95 and a beta of 1.20. The stock has a 50 day moving average price of $19.58 and a 200-day moving average price of $16.54. Embecta has a 52-week low of $9.93 and a 52-week high of $21.48.
Embecta (NASDAQ:EMBC - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.65 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.20. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. On average, analysts forecast that Embecta will post 2.87 earnings per share for the current year.
Embecta Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 14th. Investors of record on Friday, February 28th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend is Friday, February 28th. Embecta's dividend payout ratio is presently 60.00%.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on EMBC shares. Morgan Stanley raised Embecta from an "underweight" rating to an "equal weight" rating and increased their price target for the stock from $13.00 to $20.00 in a research note on Monday, December 2nd. BTIG Research upgraded Embecta from a "neutral" rating to a "buy" rating and set a $26.00 price target for the company in a report on Wednesday, November 27th.
Get Our Latest Analysis on Embecta
About Embecta
(
Get Free Report)
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Featured Stories
Before you consider Embecta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.
While Embecta currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
